{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T23:58:32Z","timestamp":1790467112814,"version":"4.1.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01595-8","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T09:35:22Z","timestamp":1784799322000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MammaTrace \u2013 a tumor na\u00efve cell-free DNA methylation test for minimal residual disease in breast cancer"],"prefix":"10.1038","volume":"10","author":[{"given":"David N.","family":"Buckley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex J.","family":"Kalfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Gooden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Lewinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Pacheco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Gayton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darcy","family":"Spicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Carpten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz-Josef","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanita","family":"Hughes Halbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caryn","family":"Lerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"O\u2019Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pockaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodour","family":"Salhia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"1595_CR1","first-page":"7","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7\u201330 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"1595_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2020.104404","volume":"114","author":"S Seltzer","year":"2020","unstructured":"Seltzer, S., Corrigan, M. & O\u2019Reilly, S. The clinicomolecular landscape of de novo versus relapsed stage IV metastatic breast cancer. Exp. Mol. Pathol. 114, 104404 (2020).","journal-title":"Exp. Mol. Pathol."},{"key":"1595_CR3","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1158\/1078-0432.CCR-23-0757","volume":"29","author":"AJ Medford","year":"2023","unstructured":"Medford, A. J. et al. Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception. Clin. Cancer Res. 29, 4540\u20134548 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1595_CR4","unstructured":"NCCN. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Breast Cancer (Version 1.2026). National Comprehensive Cancer Network (2026)."},{"key":"1595_CR5","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","volume":"616","author":"C Abbosh","year":"2023","unstructured":"Abbosh, C. et al. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature 616, 553\u2013562 (2023).","journal-title":"Nature"},{"key":"1595_CR6","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.1158\/1078-0432.CCR-18-3663","volume":"25","author":"RC Coombes","year":"2019","unstructured":"Coombes, R. C. et al. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. Clin. Cancer Res. 25, 4255\u20134263 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1595_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.annonc.2020.11.007","volume":"32","author":"MJM Magbanua","year":"2021","unstructured":"Magbanua, M. J. M. et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann. Oncol. 32, 229\u2013239 (2021).","journal-title":"Ann. Oncol."},{"key":"1595_CR8","doi-asserted-by":"publisher","first-page":"5586","DOI":"10.1158\/1078-0432.CCR-21-0410","volume":"27","author":"AR Parikh","year":"2021","unstructured":"Parikh, A. R. et al. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. Clin. Cancer Res. 27, 5586\u20135594 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1595_CR9","doi-asserted-by":"publisher","first-page":"346ra92","DOI":"10.1126\/scitranslmed.aaf6219","volume":"8","author":"J Tie","year":"2016","unstructured":"Tie, J. et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci. Transl. Med. 8, 346ra92 (2016).","journal-title":"Sci. Transl. Med."},{"key":"1595_CR10","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.18.02052","volume":"37","author":"E Christensen","year":"2019","unstructured":"Christensen, E. et al. Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. J. Clin. Oncol. 37, 1547\u20131557 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1595_CR11","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/s41375-024-02252-4","volume":"38","author":"J Chen","year":"2024","unstructured":"Chen, J. et al. Measurable residual disease (MRD)-testing in haematological and solid cancers. Leukemia 38, 1202\u20131212 (2024).","journal-title":"Leukemia"},{"key":"1595_CR12","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1158\/1078-0432.CCR-24-0590","volume":"30","author":"GJ Hanna","year":"2024","unstructured":"Hanna, G. J. et al. Personalized ctDNA for Monitoring Disease Status in Head and Neck Squamous Cell Carcinoma. Clin. Cancer Res. 30, 3329\u20133336 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1595_CR13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.annonc.2024.08.2348","volume":"36","author":"G Liu","year":"2025","unstructured":"Liu, G. et al. Clinical validation of a tissue-agnostic genome-wide methylome enrichment molecular residual disease assay for head and neck malignancies. Ann. Oncol. 36, 108\u2013117 (2025).","journal-title":"Ann. Oncol."},{"key":"1595_CR14","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687\u20131717 (2005).","journal-title":"Lancet"},{"key":"1595_CR15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1053\/j.seminhematol.2018.03.002","volume":"55","author":"TJ Pugh","year":"2018","unstructured":"Pugh, T. J. Circulating Tumour DNA for Detecting Minimal Residual Disease in Multiple Myeloma. Semin Hematol. 55, 38\u201340 (2018).","journal-title":"Semin Hematol."},{"key":"1595_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jtho.2018.09.022","volume":"14","author":"YK Chae","year":"2019","unstructured":"Chae, Y. K. & Oh, M. S. Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions. J. Thorac. Oncol. 14, 16\u201324 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"1595_CR17","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1200\/JCO.21.01929","volume":"40","author":"B Pellini","year":"2022","unstructured":"Pellini, B. & Chaudhuri, A. A. Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent. J. Clin. Oncol. 40, 567\u2013575 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1595_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1179\/1607845413y.0000000089","volume":"19","author":"V Shivarov","year":"2014","unstructured":"Shivarov, V. et al. Patient-specific microRNA expression profiles as a marker for minimal residual disease in acute myeloid leukemia. Hematology 19, 18\u201321 (2014).","journal-title":"Hematology"},{"key":"1595_CR19","doi-asserted-by":"crossref","unstructured":"Bergantim, R. et al. Detection of measurable residual disease biomarkers in extracellular vesicles from liquid biopsies of multiple myeloma patients-a proof of concept. Int. J. Mol. Sci. 23 (2022).","DOI":"10.3390\/ijms232213686"},{"key":"1595_CR20","doi-asserted-by":"publisher","first-page":"1103797","DOI":"10.3389\/fonc.2023.1103797","volume":"13","author":"AD Johnston","year":"2023","unstructured":"Johnston, A. D., Ross, J. P., Ma, C., Fung, K. Y. C. & Locke, W. J. Epigenetic liquid biopsies for minimal residual disease, what\u2019s around the corner? Front Oncol. 13, 1103797 (2023).","journal-title":"Front Oncol."},{"key":"1595_CR21","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.ygyno.2017.07.138","volume":"147","author":"RT Fortner","year":"2017","unstructured":"Fortner, R. T., Damms-Machado, A. & Kaaks, R. Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection. Gynecol. Oncol. 147, 465\u2013480 (2017).","journal-title":"Gynecol. Oncol."},{"key":"1595_CR22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/978-1-59745-522-0_25","volume":"507","author":"E Sunami","year":"2009","unstructured":"Sunami, E., Vu, A. T., Nguyen, S. L. & Hoon, D. S. Analysis of methylated circulating DNA in cancer patients\u2019 blood. Methods Mol. Biol. 507, 349\u2013356 (2009).","journal-title":"Methods Mol. Biol."},{"key":"1595_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-015-0135-8","volume":"7","author":"C Legendre","year":"2015","unstructured":"Legendre, C. et al. Whole-genome bisulfite sequencing of cell-free DNA identifies signature associated with metastatic breast cancer. Clin. Epigenetics 7, 100 (2015).","journal-title":"Clin. Epigenetics"},{"key":"1595_CR24","doi-asserted-by":"publisher","first-page":"18925","DOI":"10.3390\/ijms140918925","volume":"14","author":"YI Elshimali","year":"2013","unstructured":"Elshimali, Y. I., Khaddour, H., Sarkissyan, M., Wu, Y. & Vadgama, J. V. The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int. J. Mol. Sci. 14, 18925\u201318958 (2013).","journal-title":"Int. J. Mol. Sci."},{"key":"1595_CR25","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1586\/erm.10.17","volume":"10","author":"VV Levenson","year":"2010","unstructured":"Levenson, V. V. DNA methylation as a universal biomarker. Expert Rev. Mol. Diagn. 10, 481\u2013488 (2010).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"1595_CR26","doi-asserted-by":"crossref","unstructured":"Constancio, V., Nunes, S. P., Henrique, R. & Jeronimo, C. DNA methylation-based testing in liquid biopsies as detection and prognostic biomarkers for the four major cancer types. Cells. 9 (2020).","DOI":"10.3390\/cells9030624"},{"key":"1595_CR27","doi-asserted-by":"crossref","unstructured":"Guo, X. M., Miller, H., Matsuo, K., Roman, L. D.& Salhia B. Circulating cell-free DNA methylation profiles in the early detection of ovarian cancer: A scoping review of the literature. Cancers (Basel). 13 (2021).","DOI":"10.3390\/cancers13040838"},{"key":"1595_CR28","doi-asserted-by":"publisher","first-page":"e0150629","DOI":"10.1371\/journal.pone.0150629","volume":"11","author":"CR Legendre","year":"2016","unstructured":"Legendre, C. R. et al. Pathway implications of aberrant global methylation in adrenocortical cancer. PLoS ONE 11, e0150629 (2016).","journal-title":"PLoS ONE"},{"key":"1595_CR29","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.ccell.2022.10.022","volume":"40","author":"A Jamshidi","year":"2022","unstructured":"Jamshidi, A. et al. Evaluation of cell-free DNA approaches for multi-cancer early detection. Cancer Cell 40, 1537\u201349.e12 (2022).","journal-title":"Cancer Cell"},{"key":"1595_CR30","doi-asserted-by":"crossref","unstructured":"Chidharla, A. et al. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis. Int. J. Mol. Sci. 24 (2023).","DOI":"10.3390\/ijms241210230"},{"key":"1595_CR31","doi-asserted-by":"crossref","unstructured":"Pellini, B. et al. ctDNA MRD detection and personalized oncogenomic analysis in oligometastatic colorectal cancer from plasma and urine. JCO Precis. Oncol. 5 (2021).","DOI":"10.1200\/PO.20.00276"},{"key":"1595_CR32","doi-asserted-by":"publisher","first-page":"8152","DOI":"10.1158\/1078-0432.CCR-04-1110","volume":"10","author":"S Meng","year":"2004","unstructured":"Meng, S. et al. Circulating tumor cells in patients with breast cancer dormancy. Clin. Cancer Res. 10, 8152\u20138162 (2004).","journal-title":"Clin. Cancer Res."},{"key":"1595_CR33","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1101\/gr.183749.114","volume":"25","author":"IM Kaplow","year":"2015","unstructured":"Kaplow, I. M. et al. A pooling-based approach to mapping genetic variants associated with DNA methylation. Genome Res. 25, 907\u2013917 (2015).","journal-title":"Genome Res."},{"key":"1595_CR34","doi-asserted-by":"publisher","first-page":"lqac099","DOI":"10.1093\/nargab\/lqac099","volume":"4","author":"DN Buckley","year":"2022","unstructured":"Buckley, D. N., Gooden, G., Feng, K., Enk, J. & Salhia, B. Targeted DNA methylation from cell-free DNA using hybridization probe capture. NAR Genom. Bioinform 4, lqac099 (2022).","journal-title":"NAR Genom. Bioinform"},{"key":"1595_CR35","doi-asserted-by":"publisher","first-page":"5196","DOI":"10.1158\/1078-0432.CCR-23-1197","volume":"29","author":"DN Buckley","year":"2023","unstructured":"Buckley, D. N. et al. OvaPrint-A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer. Clin. Cancer Res. 29, 5196\u20135206 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1595_CR36","doi-asserted-by":"crossref","unstructured":"Shaw, J. A. et al. Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer. JCO Precis Oncol. e2300456 (2024).","DOI":"10.1200\/PO.23.00456"},{"key":"1595_CR37","doi-asserted-by":"publisher","first-page":"e1484","DOI":"10.1002\/widm.1484","volume":"13","author":"B Bischl","year":"2023","unstructured":"Bischl, B. et al. Hyperparameter optimization: Foundations, algorithms, best practices, and open challenges. WIREs Data Min. Knowl. Discov. 13, e1484 (2023).","journal-title":"WIREs Data Min. Knowl. Discov."},{"key":"1595_CR38","doi-asserted-by":"crossref","unstructured":"Cailleux, F. et al. Circulating tumor DNA after neoadjuvant chemotherapy in breast cancer is associated with disease relapse. JCO Precis. Oncol. e2200148 (2022).","DOI":"10.1200\/PO.22.00148"},{"key":"1595_CR39","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.ccell.2023.04.008","volume":"41","author":"MJM Magbanua","year":"2023","unstructured":"Magbanua, M. J. M. et al. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell 41, 1091\u2013102.e4 (2023).","journal-title":"Cancer Cell"},{"key":"1595_CR40","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1038\/s41591-023-02598-9","volume":"29","author":"V Anagnostou","year":"2023","unstructured":"Anagnostou, V. et al. ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. Nat. Med. 29, 2559\u20132569 (2023).","journal-title":"Nat. Med."},{"key":"1595_CR41","doi-asserted-by":"crossref","unstructured":"Tan, A. C. et al. Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer. Cancer (2024).","DOI":"10.1002\/cncr.35263"},{"key":"1595_CR42","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1159\/000524324","volume":"15","author":"G Azzi","year":"2022","unstructured":"Azzi, G. et al. Treatment Response Monitoring Using a Tumor-Informed Circulating Tumor DNA Test in an Advanced Triple-Negative Breast Cancer Patient: A Case Report. Case Rep. Oncol. 15, 473\u2013479 (2022).","journal-title":"Case Rep. Oncol."},{"key":"1595_CR43","doi-asserted-by":"crossref","unstructured":"Loupakis, F. et al. Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases. JCO Precis. Oncol. 5 (2021).","DOI":"10.1200\/PO.21.00101"},{"key":"1595_CR44","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1158\/1538-7445.AM2022-3403","volume":"82","author":"W Janni","year":"2022","unstructured":"Janni, W. et al. Abstract 3403: Multiomic, plasma-only circulating tumor DNA (ctDNA) assay identifies breast cancer patients with minimal residual disease (MRD) and predicts distant recurrence. Cancer Res. 82, 3403\u20133403 (2022).","journal-title":"Cancer Res."},{"key":"1595_CR45","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41571-020-0392-0","volume":"17","author":"A Dasari","year":"2020","unstructured":"Dasari, A. et al. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat. Rev. Clin. Oncol. 17, 757\u2013770 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1595_CR46","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","volume":"29","author":"D Kotani","year":"2023","unstructured":"Kotani, D. et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat. Med. 29, 127\u2013134 (2023).","journal-title":"Nat. Med."},{"key":"1595_CR47","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","volume":"85","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma. Eur. Urol. 85, 114\u2013122 (2024).","journal-title":"Eur. Urol."},{"key":"1595_CR48","doi-asserted-by":"crossref","unstructured":"Semenkovich, N. P. et al. Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA. J. Immunother. Cancer. 11 (2023).","DOI":"10.1136\/jitc-2022-006284"},{"key":"1595_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1119744","volume":"13","author":"Y Xu","year":"2023","unstructured":"Xu, Y. et al. Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection. Front Oncol. 13, 1119744 (2023).","journal-title":"Front Oncol."},{"key":"1595_CR50","doi-asserted-by":"crossref","unstructured":"McDonald, B. R. et al. Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. Sci. Transl. Med. 11 (2019).","DOI":"10.1126\/scitranslmed.aax7392"},{"key":"1595_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101821","volume":"39","author":"HQ Sadida","year":"2024","unstructured":"Sadida, H. Q. et al. Epigenetic modifications: Key players in cancer heterogeneity and drug resistance. Transl. Oncol. 39, 101821 (2024).","journal-title":"Transl. Oncol."},{"key":"1595_CR52","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.3389\/fonc.2020.01152","volume":"10","author":"S Romero-Garcia","year":"2020","unstructured":"Romero-Garcia, S., Prado-Garcia, H. & Carlos-Reyes, A. Role of DNA Methylation in the Resistance to Therapy in Solid Tumors. Front Oncol. 10, 1152 (2020).","journal-title":"Front Oncol."},{"key":"1595_CR53","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.molonc.2010.11.002","volume":"5","author":"S Kamalakaran","year":"2011","unstructured":"Kamalakaran, S. et al. DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables. Mol. Oncol. 5, 77\u201392 (2011).","journal-title":"Mol. Oncol."},{"key":"1595_CR54","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10549-013-2738-0","volume":"142","author":"SA Bardowell","year":"2013","unstructured":"Bardowell, S. A. et al. Differential methylation relative to breast cancer subtype and matched normal tissue reveals distinct patterns. Breast Cancer Res. Treat. 142, 365\u2013380 (2013).","journal-title":"Breast Cancer Res. Treat."},{"key":"1595_CR55","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1515\/jib-2014-236","volume":"11","author":"M List","year":"2014","unstructured":"List, M. et al. Classification of breast cancer subtypes by combining gene expression and DNA methylation data. J. Integr. Bioinform. 11, 236 (2014).","journal-title":"J. Integr. Bioinform."},{"key":"1595_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2590","volume":"12","author":"K Holm","year":"2010","unstructured":"Holm, K. et al. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res. 12, R36 (2010).","journal-title":"Breast Cancer Res."},{"key":"1595_CR57","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1093\/nar\/gku154","volume":"42","author":"H Feng","year":"2014","unstructured":"Feng, H., Conneely, K. N. & Wu, H. A Bayesian hierarchical model to detect differentially methylated loci from single nucleotide resolution sequencing data. Nucleic Acids Res. 42, e69 (2014).","journal-title":"Nucleic Acids Res."},{"key":"1595_CR58","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1101\/gr.196394.115","volume":"26","author":"F Juhling","year":"2016","unstructured":"Juhling, F. et al. metilene: fast and sensitive calling of differentially methylated regions from bisulfite sequencing data. Genome Res. 26, 256\u2013262 (2016).","journal-title":"Genome Res."},{"key":"1595_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00590-1","volume":"8","author":"DN Buckley","year":"2024","unstructured":"Buckley, D. N., Tew, B. Y., Gooden, C. & Salhia, B. A comprehensive analysis of minimally differentially methylated regions common to pediatric and adult solid tumors. NPJ Precis Oncol. 8, 125 (2024).","journal-title":"NPJ Precis Oncol."},{"key":"1595_CR60","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1093\/bioinformatics\/btr167","volume":"27","author":"F Krueger","year":"2011","unstructured":"Krueger, F. & Andrews, S. R. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics 27, 1571\u20131572 (2011).","journal-title":"Bioinformatics"},{"key":"1595_CR61","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1093\/bioinformatics\/bts503","volume":"28","author":"F Garcia-Alcalde","year":"2012","unstructured":"Garcia-Alcalde, F. et al. Qualimap: evaluating next-generation sequencing alignment data. Bioinformatics 28, 2678\u20132679 (2012).","journal-title":"Bioinformatics"},{"key":"1595_CR62","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1093\/bioinformatics\/btw354","volume":"32","author":"P Ewels","year":"2016","unstructured":"Ewels, P., Magnusson, M., Lundin, S. & Kaller, M. MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics 32, 3047\u20133048 (2016).","journal-title":"Bioinformatics"},{"key":"1595_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24994-w","volume":"12","author":"D Mathios","year":"2021","unstructured":"Mathios, D. et al. Detection and characterization of lung cancer using cell-free DNA fragmentomes. Nat. Commun. 12, 5060 (2021).","journal-title":"Nat. Commun."},{"key":"1595_CR64","doi-asserted-by":"crossref","unstructured":"Mouliere, F. et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci. Transl. Med. 10 (2018).","DOI":"10.1126\/scitranslmed.aat4921"},{"key":"1595_CR65","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41586-022-05580-6","volume":"613","author":"N Loyfer","year":"2023","unstructured":"Loyfer, N. et al. A DNA methylation atlas of normal human cell types. Nature 613, 355\u2013364 (2023).","journal-title":"Nature"},{"key":"1595_CR66","doi-asserted-by":"crossref","unstructured":"Gerds, T. A. & Kattan, M. W. Medical risk prediction models : with ties to machine learning. 1st ed. Boca Raton, FL ; Abingdon, Oxon: CRC Press (2020).","DOI":"10.1201\/9781138384484-1"},{"key":"1595_CR67","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847\u20132849 (2016).","journal-title":"Bioinformatics"},{"key":"1595_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v028.i05","volume":"28","author":"M Kuhn","year":"2008","unstructured":"Kuhn, M. Building Predictive Models in R Using the caret Package. J. Stat. Softw. 28, 1\u201326 (2008).","journal-title":"J. Stat. Softw."},{"key":"1595_CR69","unstructured":"Morgan, M. O., Valerie; Hester, Jim; Pag\u00e8s, Herv\u00e9. SummarizedExperiment: A container (S4 class) for matrix-like assays. R package version 1.38.1 ed: Bioconductor (2025)."},{"key":"1595_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin, X. et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinforma. 12, 77 (2011).","journal-title":"BMC Bioinforma."},{"key":"1595_CR71","doi-asserted-by":"crossref","unstructured":"Wickham, H. ggplot2: Elegant Graphics for Data Analysis. New York, NY: Springer (2009).","DOI":"10.1007\/978-0-387-98141-3"},{"key":"1595_CR72","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss.01686","volume":"4","author":"H Wickham","year":"2019","unstructured":"Wickham, H. et al. Welcome to the Tidyverse. J. Open Source Softw. 4, 1686 (2019).","journal-title":"J. Open Source Softw."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01595-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01595-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01595-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T23:35:16Z","timestamp":1790465716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01595-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1595"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01595-8","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B. Salhia is founder and shareholder of CpG Diagnostics and reports other support from CpG Diagnostics during the conduct of the study, as well as personal fees from AstraZeneca and Illumina outside the submitted work; in addition, B. Salhia and D. Buckley have a patent \u201cCell-Free DNA Methylation Test for breast cancer # PCT\/US2023\/081012\u201d pending and licensed to CpG Diagnostics Inc and may receive royalty payments. G. Gooden is an advisor to CpG Diagnostics. USC has an ownership interest in CpG Diagnostics and the potential to receive royalty payments from CpG Diagnostics. All other authors declare no competing financial or non-financial competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"361"}}